In conclusion, the findings from our in vitro and in vivo studies suggest that the combination of DT2216 + AZD8055 is synergistic and somewhat tumor-selective against the BCL-XL/MCL-1 co-dependent subset of SCLC and is tolerable in mice without appreciable on-target toxicity and normal tissue injury. This evidence concerns the gene BCL2L1 and neoplasm.